29
May
After posting a trio of Phase III victories, Amgen is plotting to submit the kidney dialysis drug AMG 416 for FDA review this year, charging forward with a successor to its own Sensipar.
Source: Amgen preps an FDA pitch for its late-stage kidney drug
